Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling.

Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK, Witte ON.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3395-404. doi: 10.1073/pnas.1217982109. Epub 2012 Nov 26.

2.

Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, DeGendt K, Verhoeven G, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7962-7. doi: 10.1073/pnas.1105243108. Epub 2011 Apr 25.

3.

Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Elo TD, Valve EM, Seppänen JA, Vuorikoski HJ, Mäkelä SI, Poutanen M, Kujala PM, Härkönen PL.

Neoplasia. 2010 Nov;12(11):915-27.

4.

Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.

Albertelli MA, O'Mahony OA, Brogley M, Tosoian J, Steinkamp M, Daignault S, Wojno K, Robins DM.

Hum Mol Genet. 2008 Jan 1;17(1):98-110. Epub 2007 Sep 29.

PMID:
17906287
5.

Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.

Lee SH, Luong R, Johnson DT, Cunha GR, Rivina L, Gonzalgo ML, Sun Z.

Oncogene. 2016 Feb 11;35(6):702-14. doi: 10.1038/onc.2015.117. Epub 2015 Apr 20.

6.

Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.

Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA.

Cancer Res. 2008 Jun 15;68(12):4709-18. doi: 10.1158/0008-5472.CAN-07-6289.

7.

Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.

Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC.

Cancer Res. 2005 Nov 15;65(22):10423-30.

8.

Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma.

Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK.

Clin Cancer Res. 1999 Mar;5(3):569-76.

9.

Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G, Janknecht R.

Cancer Res. 2009 Oct 15;69(20):8102-10. doi: 10.1158/0008-5472.CAN-09-0941. Epub 2009 Sep 29.

10.

Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.

Zhu C, Luong R, Zhuo M, Johnson DT, McKenney JK, Cunha GR, Sun Z.

J Biol Chem. 2011 Sep 23;286(38):33478-88. doi: 10.1074/jbc.M111.269894. Epub 2011 Jul 27.

11.

Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA.

Oncogene. 2008 Nov 27;27(56):7118-30. doi: 10.1038/onc.2008.293. Epub 2008 Aug 25.

12.

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.

Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON.

Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70. doi: 10.1073/pnas.0905931106. Epub 2009 Jul 10.

13.

FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM.

Cancer Res. 2014 Jan 15;74(2):609-20. doi: 10.1158/0008-5472.CAN-13-1093. Epub 2013 Dec 4.

14.

Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.

Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA.

Oncogene. 2011 Jan 13;30(2):167-77. doi: 10.1038/onc.2010.400. Epub 2010 Sep 6.

15.

Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Leach DA, Need EF, Toivanen R, Trotta AP, Palethorpe HM, Tamblyn DJ, Kopsaftis T, England GM, Smith E, Drew PA, Pinnock CB, Lee P, Holst J, Risbridger GP, Chopra S, DeFranco DB, Taylor RA, Buchanan G.

Oncotarget. 2015 Jun 30;6(18):16135-50. Erratum in: Oncotarget. 2015 Nov 3;6(34):36923. Palenthorpe, Helen M [Corrected to Palethorpe, Helen M].

16.

HMGA2 expression in a canine model of prostate cancer.

Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I, Bullerdiek J.

Cancer Genet Cytogenet. 2007 Sep;177(2):98-102.

PMID:
17854662
17.

Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R.

Am J Pathol. 2004 Aug;165(2):533-40.

18.

MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, De Marzo AM.

PLoS One. 2010 Feb 25;5(2):e9427. doi: 10.1371/journal.pone.0009427.

19.

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.

20.

Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.

Hill R, Song Y, Cardiff RD, Van Dyke T.

Cell. 2005 Dec 16;123(6):1001-11.

Supplemental Content

Support Center